MINOCYCLINE HYDROCHLORIDE | N050781 | ORAPHARMA INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Janssen Research & Development, LLC | 305 | 2024-02-16 → 2030-06-30 | |
| N/A | Active | Jordan University of Science and Technology | 40 | 2010-06-28 → 2030-12-01 | |
| Early Phase 1 | Not Yet Recruiting | Medical University of South Carolina | 35 | 2026-09-15 → 2028-02 | |
| Phase 2 | Not Yet Recruiting | Baystate Medical Center | 60 | 2025-07 → 2028-01-24 | |
| Phase 2 | Not Yet Recruiting | Barbara Ann Karmanos Cancer Institute | 61 | 2026-09 → 2031-06-30 | |
| Phase 4 | Not Yet Recruiting | Qilu Hospital of Shandong University | 316 | 2026-08-01 → 2028-08-10 | |
| Phase 4 | Not Yet Recruiting | Qilu Hospital of Shandong University | 492 | 2026-09-01 → 2027-12-30 | |
| Phase 3 | Recruiting | University of Nebraska | 400 | 2007-12-10 → 2029-03 | |
| Phase 3 | Recruiting | Beijing Tiantan Hospital | 934 | 2026-06-05 → 2028-12-31 | |
| N/A | Completed | University of Oxford | 40 | 2017-04-26 → 2018-10-25 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
Lowest Price
$41.35
Highest Price
$220.75
FSS NDCs
2
Big4 NDCs
2
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 65976-0100-01ARESTIN 1MG CARTRIDGE | $41.35 | Big4 | Bausch Health US, LLC | 04/30/2026 |
| 65976-0100-01ARESTIN 1MG CARTRIDGE | $99.64 | FSS | Bausch Health US, LLC | 04/30/2026 |
| 65976-0100-24ARESTIN 1MG CARTRIDGE | $220.75 | Big4 | Bausch Health US, LLC | 04/30/2026 |
| 65976-0100-24ARESTIN 1MG CARTRIDGE | $220.75 | FSS | Bausch Health US, LLC | 04/30/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
Total Spending
$5.1M
Total Claims
1,166
Beneficiaries
1,027
Avg Cost/Unit
$102.76
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
7 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| May 28, 2024 | SUPPL -25 | View Letter (PDF) |
| May 10, 2017 | SUPPL -20 | View Letter (PDF) |
| Jul 31, 2012 | SUPPL -19 | View Letter (PDF) |
| Feb 20, 2008 | SUPPL -12 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.